Navigation Links
Derma Sciences Reports Fourth Quarter, Year-End Results for 2008
Date:4/1/2009

PRINCETON, N.J., April 1 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, reported that sales for 2008 rose 47.1% year-over-year, reflecting incremental sales from its First Aid Division (FAD) and higher sales of proprietary advanced wound care products led by MEDIHONEY(R). Sales for the year were $50.2 million vs $34.1 million in 2007. The Company's loss increased consistent with expectations to $4.0 million or $0.10 per share, compared to 2007's loss of $2.3 million or $0.09 per share, as Derma Sciences implemented its advanced wound care growth strategy, integrated FAD into the company and continued its investment in R&D. Fourth quarter 2008 sales were $12.6 million versus $10.7 million in 2007. Net losses diminished each quarter during the year, and the 2008 fourth quarter loss was $0.6 million versus $2.0 million in 2007.

Chairman and CEO Ed Quilty commented, "Our advanced wound care products made great strides in 2008. Sales for our silver alginate product, ALGICELL(R) Ag, nearly doubled to over $1.1 million. Sales of our MEDIHONEY product, launched in October 2007, grew consistently each quarter, and ended the year at $1.5 million in 2008 versus $0.1 million for the final three months of 2007. MEDIHONEY continues to get great media coverage, typified by a cluster of television and print articles reporting that the product was credited for saving a patient's leg from having to be amputated at Long Island Jewish Hospital in January 2009. Its coverage in medical journals continues to be strong, as seven separate articles on the emerging use of MEDIHONEY were published in the major wound care journals since December of 2008.

"In the fourth quarter and early 2009, we launched three additional promising new products," Quilty stated. "Our prop
'/>"/>

SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Derma Sciences to Report 2008 Fourth Quarter and Year-End Results on April 1, 2009
2. Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced
3. Wendy E. Roberts, MD, Named 2009-2010 President of the Womens Dermatologic Society
4. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
5. Palomar Medical to Debut New Devices and a More Powerful Platform at the American Academy of Dermatology Annual Meeting
6. Aesthera Announces Breakthrough Innovations at 2009 American Academy of Dermatology (AAD) Meeting
7. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
8. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
9. Professional Skin Care Company OrthoNeutrogena Becomes Ortho Dermatologics
10. American Academy of Dermatology Issues New Guidelines For The Management of Psoriasis With Topical Therapies
11. Derma Sciences Gains FDA Clearance for Novel BIOGUARD(TM) Barrier Dressing with NIMBUS(R) Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... This is a professional and in-depth study on ... a focus on the Chinese market. The report provides ... manufacturers and is a valuable source of guidance and ... , Firstly, the report provides a basic overview of ... Then, the report explores the international and Chinese major ...
(Date:12/19/2014)... THURSDAY, Dec. 18, 2014 (HealthDay News) -- A new ... -- moderate to severe hot flashes and night sweats ... bones. Hot flashes are common during menopause, affecting ... menopause also affect women after menopause, since they then ... "Our findings suggest women who exhibit moderate or ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- Traveling through the ... measles virus to three others within a four-hour time ... a new report shows. "The exposures in this ... rather than an international terminal, highlighting the fact that ... Jared Vega, an infectious disease specialist at the U.S. ...
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of a ... Future” and co-founder of the Ace Medical Weight Loss Center ... a broad look at the industry of weight loss, and ... On film and in television shows, however, she says the ... aspects and played for basic laughs, which she believes impacts ...
(Date:12/17/2014)... 2014 A group of 127 scientists sent ... in reaction to a recent statement by the center that ... and derogated the efficacy of all brain exercises. , Signatories ... parts of the center’s statement critical of brain exercise companies ... also overstated its case, in a document it had entitled ...
Breaking Medicine News(10 mins):Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 2Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 3Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 4Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 5Health News:Gliquidone Industry Global and China Analysis for 2019, Now Available at ReportsnReports.com 6Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4
... in CT scanner technology have made perfusion computed tomography ... suspected stroke. Now, researchers at Mayo Clinic are working ... other CT images. Mayo Clinic medical physicist Cynthia McCollough, ... related to CT dose reduction at the 52nd Annual ...
... and Massachusetts believe the Earth has been getting warmer ... percent and 84 percent, respectively), and large majorities favor ... new public opinion research by Professor Jon Krosnick, a ... at Stanford University. Following up on a ...
... A major breakthrough in how to target and destroy ... been made by researchers at Wake Forest University Baptist ... to target and destroy Glioblastoma multiforme (GBM) cells without ... possibilities in cancer research previously not known to be ...
... found a new mechanism that explains how certain immune ... or pathological antibodies such as those present in autoimmune ... published online in the September issue of Nature ... Professor of Medicine at Mount Sinai School of Medicine, ...
... By Ellin Holohan HealthDay Reporter , TUESDAY, ... rising, their quality of life is falling, according to new ... healthy days per year that Americans lose due to obesity ... about 7.5 in 1993 to 17 in 2008. Researchers ...
... HealthDay Reporter , MONDAY, Aug. 2 (HealthDay News) ... A new two-year study suggests that it may not ... about eating and exercise, people lost about the same amount ... or a traditional low-fat diet. "In general, dieters should ...
Cached Medicine News:Health News:Mayo Clinic researchers share latest findings in CT radiation dose reduction efforts 2Health News:New state surveys affirm Americans' support for government action on climate change 2Health News:New state surveys affirm Americans' support for government action on climate change 3Health News:Scientists develop 'designer protein,' opening new door in cancer research 2Health News:Scientists develop 'designer protein,' opening new door in cancer research 3Health News:New drug target for immune diseases discovered 2Health News:Weight Gain Eroding Americans' Quality of Life 2Health News:Weight Gain Eroding Americans' Quality of Life 3Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 2Health News:Low Carb-, Low-Fat Diets Tied for Long-Term Weight Loss 3
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... addition of the "MEMS Gyroscopes Analog Devices ... report to their offering. ... for tactical grade applications made a lot of ... of reliability. They are now accepted in high-reliability ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... 04, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.'s lead drug ... the treatment of hot flashes associated with ... in the company's,double-blind, placebo- controlled, randomized Phase ... moderate to severe hot flashes,per week were ...
... analyses of progression-free survival in,the SPARC Phase ... risk of disease progression for patients receiving,satraplatin. ... well as presence or absence of pain., ... and GPC Biotech AG today announced the ...
Cached Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 2Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 3Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 4Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 5Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 6Additional New Data from Satraplatin SPARC Phase 3 Investigational,Trial Presented at ASCO Annual Meeting 7
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
Inquire...
Medicine Products: